|
|
|
11-50 employees
View all
|
|
Biotechnology
|
|
New York,NY,US
|
|
Treadwell Therapeutics is a clinical-stage biotechnology company developing novel therapeutics for highly aggressive cancers by targeting critical tumor-specific vulnerabilities including aneuploidy and immunogenicity. The Company’s robust, internally developed pipeline includes novel small molecule drugs in single agent and combination studies. Lead candidate, CFI-400945, is a PLK4 inhibitor in multiple Phase 1 and Phase 2 trials including for TNBC, prostate cancer and AML. Additional product candidates include CFI-402257, a clinical stage TTK inhibitor, as well as CFI-402411, a preclinical HPK1 inhibitor (IND filing 1H20), which is positioned to be the first clinical stage small molecule modulator of a unique node of T cell activation and has a mechanism distinct from PD1/PDL1. Interested in joining Treadwell Therapeutics? Visit our Career page: https://treadwelltx.com/careers/
|
Treadwell Therapeutics, Inc. Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used Treadwell Therapeutics, Inc. email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact Treadwell Therapeutics, Inc. customer service number in your country click here to find.
Roger Sidhu is the CEO of Treadwell Therapeutics, Inc.. Or you may call 18177247311
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.